For: | Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol 2016; 6(1): 1-19 [PMID: PMC4804243 DOI: 10.5662/wjm.v6.i1.1] |
---|---|
URL: | https://www.wjgnet.com/2222-0682/full/v6/i1/1.htm |
Number | Citing Articles |
1 |
George Kontoghiorghes, Christina Kontoghiorghe. Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells 2020; 9(6): 1456 doi: 10.3390/cells9061456
|
2 |
Yu Peng, Xuejiao Chang, Minglin Lang. Iron Homeostasis Disorder and Alzheimer’s Disease. International Journal of Molecular Sciences 2021; 22(22): 12442 doi: 10.3390/ijms222212442
|
3 |
Shalini S. Rao, Paul Anthony Adlard. Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration. Frontiers in Molecular Neuroscience 2018; 11 doi: 10.3389/fnmol.2018.00276
|
4 |
Pustika A. Wahidiyat, Ellen Wijaya, Soedjatmiko Soedjatmiko, Ina S. Timan, Vasili Berdoukas, Mikhael Yosia. Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells, Molecules, and Diseases 2019; 77: 67 doi: 10.1016/j.bcmd.2019.03.007
|
5 |
Sarina Entezari, Seyedeh Mona Haghi, Narges Norouzkhani, Barsa Sahebnazar, Fatemeh Vosoughian, Diba Akbarzadeh, Muhammad Islampanah, Navid Naghsh, Mohammad Abbasalizadeh, Niloofar Deravi, Yasmina Abd Elhakim. Iron Chelators in Treatment of Iron Overload. Journal of Toxicology 2022; 2022: 1 doi: 10.1155/2022/4911205
|
6 |
Kathleen E. Sullivan, Natalie D. Mylniczenko, Steven E. Nelson, Brandy Coffin, Shana R. Lavin. Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros bicornis). Animals 2020; 10(11): 1991 doi: 10.3390/ani10111991
|
7 |
Abdul Hakim Md Yusop, Ahmed Al Sakkaf, Hadi Nur. Modifications on porous absorbable Fe‐based scaffolds for bone applications: A review from corrosion and biocompatibility viewpoints. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2022; 110(1): 18 doi: 10.1002/jbm.b.34893
|
8 |
Xiaojiao Zheng, Xu Wang, Zifang Ding, Wei Li, Ying Peng, Jiang Zheng. Metabolic activation of deferiprone mediated by CYP2A6. Xenobiotica 2021; 51(11): 1282 doi: 10.1080/00498254.2021.1931729
|
9 |
Yuting Wu, Jinfeng Liu, Mingxiao Shao, Pei Zhang, Shaohua Song, Ge Yang, Xicheng Liu, Zhe Liu. Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents. Journal of Inorganic Biochemistry 2022; 233: 111855 doi: 10.1016/j.jinorgbio.2022.111855
|
10 |
Maria Domenica Cappellini, John B. Porter, Vip Viprakasit, Ali T. Taher. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. Blood Reviews 2018; 32(4): 300 doi: 10.1016/j.blre.2018.02.001
|
11 |
Fredson Torres Silva, Breno Pannia Espósito. Intracellular Iron Binding and Antioxidant Activity of Phytochelators. Biological Trace Element Research 2022; 200(8): 3910 doi: 10.1007/s12011-021-02965-y
|
12 |
L. Ma, M. Gholam Azad, M. Dharmasivam, V. Richardson, R.J. Quinn, Y. Feng, D.L. Pountney, K.F. Tonissen, G.D. Mellick, I. Yanatori, D.R. Richardson. Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies. Redox Biology 2021; 41: 101896 doi: 10.1016/j.redox.2021.101896
|
13 |
Annita Kolnagou, Marios Kleanthous, George J. Kontoghiorghes. Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease. Frontiers in Bioscience-Elite 2022; 14(3) doi: 10.31083/j.fbe1403018
|
14 |
Geir Bjørklund, David R. Wallace, Tony Hangan, Monica Butnariu, Leonard Gurgas, Massimiliano Peana. Cerebral iron accumulation in multiple sclerosis: Pathophysiology and therapeutic implications. Autoimmunity Reviews 2025; 24(4): 103741 doi: 10.1016/j.autrev.2025.103741
|
15 |
George J. Kontoghiorghes. Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. International Journal of Molecular Sciences 2023; 24(5): 4970 doi: 10.3390/ijms24054970
|
16 |
Muhan Deng, Changhan Liao, Xiufeng Wang, Shangda Chen, Fugang Qi, Xueliang Zhao, Peng Yu. A paper-based colorimetric microfluidic sensor fabricated by a novel spray painting prototyping process for iron analysis. Canadian Journal of Chemistry 2019; 97(5): 373 doi: 10.1139/cjc-2018-0346
|
17 |
Sadegh Kaviani, Mohammad Izadyar, Mohammad Reza Housaindokht. A DFT study on the metal ion selectivity of deferiprone complexes. Computational Biology and Chemistry 2020; 86: 107267 doi: 10.1016/j.compbiolchem.2020.107267
|
18 |
Gülüzar Özbolat, Arash Alizadeh Yegani. Effects of Curcumin on Iron Overload in Rats. Sudan Journal of Medical Sciences 2021; 16(4) doi: 10.18502/sjms.v16i4.9944
|
19 |
George J. Kontoghiorghes. Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients. International Journal of Molecular Sciences 2022; 23(3): 1364 doi: 10.3390/ijms23031364
|
20 |
Nupura Manish Prabhune, Bilal Ameen, Sudharshan Prabhu. Therapeutic potential of synthetic and natural iron chelators against ferroptosis. Naunyn-Schmiedeberg's Archives of Pharmacology 2024; doi: 10.1007/s00210-024-03640-4
|
21 |
Yao Lu, Guotong Ruan, Wei Du, Jie Li, Naidi Yang, Qiong Wu, Li Lu, Chengwu Zhang, Lin Li. Recent progress in rational design of fluorescent probes for Fe2+ and bioapplication. Dyes and Pigments 2021; 190: 109337 doi: 10.1016/j.dyepig.2021.109337
|
22 |
Gülüzar Özbolat, Arash Alizadeh Yegani, Abdullah Tuli. Synthesis, characterization and electrochemistry studies of iron(III) complex with curcumin ligand. Clinical and Experimental Pharmacology and Physiology 2018; 45(11): 1221 doi: 10.1111/1440-1681.12964
|
23 |
Saideh Fakharzadeh, Hassan Argani, Simin Dadashzadeh, Somayeh Kalanaky, Peyman Mohammadi Torbati, Mohammad Hassan Nazaran, Abbas Basiri. <p>BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020; : 1179 doi: 10.2147/DMSO.S240757
|
24 |
George J. Kontoghiorghes. Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines 2021; 8(7): 36 doi: 10.3390/medicines8070036
|
25 |
Mikhael Yosia, Pustika Amalia Wahidiyat. Side effect of deferiprone as iron chelator in patient with thalassemia. Paediatrica Indonesiana 2018; 57(6): 329 doi: 10.14238/pi57.6.2017.329-36
|
26 |
Vicki Osborne, Miranda Davies, Deborah Layton, Saad A. W. Shakir. Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England. Drug Safety 2018; 41(3): 267 doi: 10.1007/s40264-017-0606-2
|
27 |
Niloofar Deravi, Narges Norouzkhani, Kimia Keylani, Seyedeh Mona Haghi, Seyyed Kiarash Sadat Rafiei. Encyclopedia of Toxicology. 2024; : 519 doi: 10.1016/B978-0-12-824315-2.00591-1
|
28 |
Maryam Hafizi, Somayeh Kalanaky, Saideh Fakharzadeh, Pegah Karimi, Atefeh Fakharian, Somayeh Lookzadeh, Esmaeil Mortaz, Maryam Sadat Mirenayat, Jalal Heshmatnia, Mehrdad Bakhshayesh Karam, Homa Zamani, Alireza Nadji, Mihan Pourabdollah Toutkaboni, Saeed Oraee-Yazdani, Mohammad Esmaeil Akbari, Hamidreza Jamaati, Mohammad Hassan Nazaran. Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial. Trials 2023; 24(1) doi: 10.1186/s13063-023-07624-2
|
29 |
Agnieszka Szczerbinska, Beata Kasztelan-Szczerbinska, Anna Rycyk-Bojarzynska, Janusz Kocki, Halina Cichoz-Lach. Hemochromatosis—How Not to Overlook and Properly Manage “Iron People”—A Review. Journal of Clinical Medicine 2024; 13(13): 3660 doi: 10.3390/jcm13133660
|
30 |
Mecit Ozdemir, Yi Zhang, Maolin Guo. A highly selective “off-on” fluorescent sensor for subcellular visualization of labile iron(III) in living cells. Inorganic Chemistry Communications 2018; 90: 73 doi: 10.1016/j.inoche.2018.02.015
|
31 |
Rawan Eid, Nagla T.T. Arab, Michael T. Greenwood. Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2017; 1864(2): 399 doi: 10.1016/j.bbamcr.2016.12.002
|
32 |
George Kontoghiorghes, Annita Kolnagou, Theodora Demetriou, Marina Neocleous, Christina Kontoghiorghe. New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications. International Journal of Molecular Sciences 2021; 22(11): 5546 doi: 10.3390/ijms22115546
|
33 |
George J. Kontoghiorghes. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences 2023; 24(23): 16749 doi: 10.3390/ijms242316749
|
34 |
Joshua P. Gray, Natalia Suhali-Amacher, Sidhartha D. Ray. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Side Effects of Drugs Annual 2017; 39: 197 doi: 10.1016/bs.seda.2017.07.001
|
35 |
Charles Badu-Boateng, Richard J. Naftalin. Ascorbate and ferritin interactions: Consequences for iron release in vitro and in vivo and implications for inflammation. Free Radical Biology and Medicine 2019; 133: 75 doi: 10.1016/j.freeradbiomed.2018.09.041
|
36 |
Yuting Wu, Jinfeng Liu, Mingxiao Shao, Pei Zhang, Shaohua Song, Ge Yang, Xicheng Liu, Zhe Liu. Cyclometalated Iridium(Iii) Dithioformic Acid Complexes as Mitochondria-Targeted Imaging and Anticancer Agents. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4067037
|